Sen. Ron Wyden Sells Off Shares of Pfizer Inc. (NYSE:PFE)

Senator Ron Wyden (D-Oregon) recently sold shares of Pfizer Inc. NYSE: PFE. In a filing disclosed on July 02nd, the Senator disclosed that they had sold between $1,001 and $15,000 in Pfizer stock on June 3rd.

Pfizer Trading Down 0.8%

Shares of Pfizer stock traded down $0.21 on Monday, reaching $24.27. The company had a trading volume of 33,436,955 shares, compared to its average volume of 41,926,715. The firm has a market cap of $137.96 billion, a price-to-earnings ratio of 7.62, a P/E/G ratio of 0.89 and a beta of 0.58. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.26 and a quick ratio of 0.96. The firm's 50-day moving average price is $24.07 and its two-hundred day moving average price is $24.71. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.67 by $0.25. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The company had revenue of $13.72 billion during the quarter, compared to analysts' expectations of $14.43 billion. During the same quarter in the previous year, the business earned $0.82 EPS. Pfizer's revenue was down 7.8% compared to the same quarter last year. As a group, research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 7.09%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer's dividend payout ratio is presently 124.64%.

Analyst Ratings Changes

Several research analysts have recently commented on PFE shares. HSBC reduced their price target on Pfizer from $27.00 to $26.00 and set a "buy" rating for the company in a research report on Monday, May 19th. TD Cowen lowered their target price on Pfizer from $32.00 to $28.00 and set a "hold" rating on the stock in a research note on Tuesday, April 22nd. Berenberg Bank lowered their price target on Pfizer from $28.00 to $25.00 and set a "hold" rating on the stock in a research report on Thursday, May 29th. Jefferies Financial Group increased their target price on Pfizer from $32.00 to $33.00 and gave the company a "buy" rating in a report on Wednesday, May 21st. Finally, The Goldman Sachs Group increased their price target on Pfizer from $25.00 to $27.00 and gave the company a "neutral" rating in a report on Wednesday, April 30th. One investment analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, six have assigned a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $28.55.

Hedge Funds Weigh In On Pfizer

Several hedge funds have recently bought and sold shares of PFE. HighMark Wealth Management LLC boosted its holdings in Pfizer by 123.7% in the second quarter. HighMark Wealth Management LLC now owns 4,249 shares of the biopharmaceutical company's stock valued at $103,000 after acquiring an additional 2,350 shares during the last quarter. DHJJ Financial Advisors Ltd. increased its holdings in Pfizer by 44.7% in the second quarter. DHJJ Financial Advisors Ltd. now owns 1,959 shares of the biopharmaceutical company's stock valued at $47,000 after buying an additional 605 shares during the last quarter. Abundance Wealth Counselors increased its holdings in Pfizer by 21.3% in the second quarter. Abundance Wealth Counselors now owns 37,849 shares of the biopharmaceutical company's stock valued at $917,000 after buying an additional 6,649 shares during the last quarter. Hilltop National Bank acquired a new position in Pfizer in the second quarter valued at approximately $518,000. Finally, Triad Wealth Partners LLC acquired a new position in Pfizer in the second quarter valued at approximately $212,000. Hedge funds and other institutional investors own 68.36% of the company's stock.

About Senator Wyden

Ron Wyden (Democratic Party) is a member of the U.S. Senate from Oregon. He assumed office on January 30, 1996. His current term ends on January 3, 2029. Wyden (Democratic Party, Independent Party) ran for re-election to the U.S. Senate to represent Oregon. He won in the general election on November 8, 2022. He advanced from the Democratic primary on May 17, 2022. In 2018, the Town Hall Project, which described itself as "a citizen powered, grassroots effort that empowers constituents across the country to have face-to-face conversations with their elected representatives," named Wyden town hall MVP for the second year in a row. According to OregonLive, Wyden held over 900 town hall meetings between 1996 and 2018. Wyden previously served in the U.S. House of Representatives, representing Oregon's 3rd Congressional District from 1981 to 1996. As of a 2014 analysis of multiple outside rankings, Wyden is an average Democratic member of Congress, meaning he will vote with the Democratic Party on the majority of bills.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.